Clairity Breast is FDA-authorized AI software predicting five-year breast cancer risk from screening mammograms.
Clairity Breast (FDA-authorized under the device name Allix5) is a mammography-based artificial-intelligence risk-prediction platform from Clairity, Inc. It analyzes a bilateral screening mammogram to estimate the probability that a patient will develop breast cancer within five years, with the model trained on millions of images and validated across more than 77,000 mammograms from five screening centers.
The platform is designed to complement radiologist workflow after mammogram interpretation and became available to consumers nationwide through Everlywell in October 2026, with first clinical use at Beth Israel Deaconess Medical Center in February 2026.
Icad
ProFound AI Risk
icadmed.com
Lunit
Risk Pathways
lunit.io
RadNet
SmartMammo Breast Solutions
radnet.com
| Attribute | Clairity Breast | ProFound AI Risk | Risk Pathways | SmartMammo Breast Solutions | |
|---|---|---|---|---|---|
| Provider | | | Lunitlunit.ioPublic | | |
| Founded | 2020 | 1984 | 2013 | 1981 | |
| Sells To | Enterprise | Enterprise | — | — | |
| Pricing Model | Recurring, Software | Recurring, Software, Transactional | — | Transactional | |
| Ownership | Private, Venture-backed | Public | Public | Public |
Provider
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private, Venture-backed
Provider
Founded 1984
Sells To Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
Founded 2013
Sells To —
Pricing Model —
Ownership Public
Provider
Founded 1981
Sells To —
Pricing Model Transactional
Ownership Public
AI-powered clinical tests for breast cancer treatment selection, integrating pathology and clinical data to predict recurrence risk and therapy response.
AI-powered clinical tests for breast cancer treatment selection, integrating pathology and clinical data to predict recurrence risk and therapy response.